Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Samsung Biologics","sponsor":"STCube ","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and STCube Enter into Development and Manufacturing Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Biologics"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Panolos","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics Signs Development Agreement with Panolos for Solid Tumor Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Biologics"},{"orgOrder":0,"company":"LegoChem Biosciences","sponsor":"Iksuda Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChem Biosciences and Iksuda Therapeutics Expand License Agreement for Development of Antibody-Drug Conjugates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"LegoChem Biosciences"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Y-Biologics and Pierre Fabre Sign an Exclusive License Agreement in the Field Of Immuno-Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Y-Biologics"},{"orgOrder":0,"company":"IntoCell","sponsor":"Cellectar","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"IntoCell"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"DynamiCure","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA at Korea-US Digital\u00b7BioHealth Business Forum","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"OliX Pharmaceutical"},{"orgOrder":0,"company":"Samsung Biologics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$411.0 million","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and Pfizer Announce Strategic Collaboration for Long-Term Manufacturing of Biosimilars Portfolio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Samsung Biologics"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Samsung Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Samsung Biologics and Pfizer Announce Strategic Collaboration for Long-Term Manufacturing of Biosimilars Portfolio

              Details:

              Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio covering oncology, inflammation, and immunology.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pfizer Inc

              Deal Size: $411.0 million Upfront Cash: Undisclosed

              Deal Type: Collaboration June 08, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OliX Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OliX Pharmaceuticals Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA at Korea-US Digital·BioHealth Business Forum

              Details:

              Companies signed a memorandum of understanding, for developing an RNA-based antibody-drug conjugate (ADC) therapeutics at the Korea-US Digital·BioHealth Business Forum.

              Lead Product(s): RNA-based Antibody-drug Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: DynamiCure

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IntoCell

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc

              Details:

              The collaboration focuses on combining IntoCell’s validated novel Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker chemistry with Cellectar’s validated novel targeting platform, phospholipid ethers (PLEs) to develop new PDCs.

              Lead Product(s): Phospholipid Drug Conjugates

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cellectar

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Expanded Collaboration July 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Y-Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Y-Biologics and Pierre Fabre Sign an Exclusive License Agreement in the Field Of Immuno-Oncology

              Details:

              The agreement grants Pierre Fabre the worldwide exclusive rights to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax®-ABL library owned by Y-Biologics.

              Lead Product(s): Human Antibody-based Therapeutic

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Pierre Fabre

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LegoChem Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LegoChem Biosciences and Iksuda Therapeutics Expand License Agreement for Development of Antibody-Drug Conjugates

              Details:

              Expanded agreement grants Iksuda access to LegoChem Biosciences’ next generation ADC platform for up to six targets. Iksuda also gains access to LegoChem Biosciences’ new payload, supplementing the tumour-activated payloads accessed in 2020.

              Lead Product(s): Antibody-drug Conjugate

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Iksuda Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Samsung Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Samsung Biologics Signs Development Agreement with Panolos for Solid Tumor Treatment

              Details:

              Samsung Biologics will provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing for Panolos Bioscience's PB101, an Fc-fusion protein intended to treat solid tumors.

              Lead Product(s): PB101

              Therapeutic Area: Oncology Product Name: PB101

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Panolos

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Samsung Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag South Korea
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Samsung Biologics and STCube Enter into Development and Manufacturing Agreement

              Details:

              Samsung Biologics will offer a wide range of services from cell line development, process development, manufacturing of non-clinical and clinical material, to IND submission for STCube.

              Lead Product(s): STT-003

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: STCube

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY